SCHEMBL761096

SCHEMBL761096

O=C(Nc1ccc(C(F)(F)F)cc1Cl)n1cc[c]n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
ALDH1A1 P00352 4/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
NTRK1 P04629 2/20 0.44
ACHE P22303 1/20 0.43
CCR1 P32246 1/20 0.42
IDH1 O75874 1/20 0.40
PLCG1 P19174 1/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CHRNA7 P36544 1/20 0.39
CSNK1D P48730 1/20 0.39
CSNK1E P49674 1/20 0.39
ALOX15 P16050 1/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754980 0.90 CHRNA7 (0.50) MAPTALDH1A1LMNACHRNA7MEN1
SCHEMBL752990 0.77 MAPT (0.54) MAPTMEN1POLBKMT2AMAPK1
SCHEMBL11028201 0.74 MEN1 (0.52) MAPTALDH1A1LMNAMEN1POLB
SCHEMBL752278 0.73 MEN1 (0.49) MAPTALDH1A1LMNAMEN1POLB
SCHEMBL27672060 0.71 ALDH1A1 (0.63) MAPTALDH1A1CA12CA1CA2
SCHEMBL22057590 0.71 ALDH1A1 (0.59) MAPTALDH1A1CA12CA1CA2
SCHEMBL31090296 0.71 ALDH1A1 (0.59) MAPTALDH1A1CA12CA1CA2
SCHEMBL755622 0.71 NPC1 (0.44) MAPTALDH1A1LMNAPKMNPSR1
SCHEMBL7364824 0.70 TAS1R3 (0.45) MAPTALDH1A1CA12CA2CA9
SCHEMBL25037396 0.69 ACHE (0.57) MAPTALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD MAPT 3169/4885ALDH1A1 4785/4885TRPM8 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.